LobbyingSpyre Therapeutics lobbying by quarter
Spyre Therapeutics SYRE's latest lobbying report covers Q2 2026, at $10K. The four quarters Q4 2025–Q3 2026 total $60K. Its first report covers Q4 2025; the issues it reports most are Health Issues.
Spyre TherapeuticsSYRE
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $60K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q4 2025
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2025 | $10K | 1 |
| Q1 2026 | $40K | 1 |
| Q2 2026 | $10K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$60K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
- Executive Office of the President (EOP)1 reports
- Food & Drug Administration (FDA)1 reports
- Office of Management & Budget (OMB)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Arnold & Porter Kaye Scholer | $60K | 3 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| LUKE ALBERT | Intern, Rep. Horn (2019) | Q1 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Arnold & Porter Kaye Scholer | $10K |
| 04/20for Q1 | Arnold & Porter Kaye Scholer | $40K |
| 01/15for Q4 2025 | Arnold & Porter Kaye Scholer | $10K |
| 25/11/17for Q4 2025 | Arnold & Porter Kaye Scholer | Under $5,000 |